Sector Directory



Vaxine Pty Ltd

Vaxine was founded in 2002 as a spin out of the National Health Sciences Centre (NHSC) in Canberra to develop novel vaccine technologies. Vaxine is situated within the Flinders University precinct in Adelaide providing Vaxine with ideal opportunities for bench to bedside vaccine research and development.

Vision CRC

The Vision Cooperative Research Centre (Vision CRC) Ltd was established in 2003 under the Australian Government's Business Cooperative Research Centres Programme and funded for twelve years, from 2003-2015.

WE Buchan

WE Buchan are an integrated public relations and communication agency, developing strategies that effectively cut through the clutter. Theycombine traditional and digital strategies to bring campaigns to life through meaningful brand engagement and exposure.

Westmead Institute for Medical Research

The Westmead Institute for Medical Research (WIMR) is one of the largest medical research institutes in Australia conducting research across infectious and immune diseases; cancer and leukaemia; liver and metabolic diseases; eye and brain related disorders and heart and respiratory disorders.

Wonder Drug Consulting Pty Ltd

MAESTrO is a large, comprehensive, on-line database of resources and submissions that display related outcomes for health care technologies of many types (medicine, vaccines, blood products, devices, procedures, cellular therapies and gene therapies) to the world's major regulatory and reimbursement/health technology agencies.

Wound Management Innovation CRC

The Wound Management Innovation Cooperative Research Centre (WMI CRC) has been a catalyst for change in the wound industry since its inception in 2010.

Wrays

Wrays is an independent IP specialist firm in Australia with significant experience in the recognition, protection and prosecution of intellectual property (IP) rights across a broad range of industries and technologies.

Xerion Limited

Xerion is dedicated to transforming innovations in life sciences into viable business opportunities that improves quality of life. The company currently has two major business units: a dermatology business and a medical device business.

Zucero Therapeutics Ltd

Zucero Therapeutics is an Australian-based biotechnology company committed to the discovery and development of modified sugar compounds for the treatment of cancer. Pixatimod (PG545) has emerged as Zucero’s first clinical candidate and is classified as an immunomodulatory agent that enhances the host immune system’s ability to suppress cancer.